Literature DB >> 33783985

Landscape and dynamics of single tumor and immune cells in early and advanced-stage lung adenocarcinoma.

Zhencong Chen1, Yiwei Huang1, Zhengyang Hu1, Mengnan Zhao1, Ming Li1, Guoshu Bi1, Yuansheng Zheng1, Jiaqi Liang1, Tao Lu1, Wei Jiang1, Songtao Xu1, Cheng Zhan1, Junjie Xi1, Qun Wang1, Lijie Tan1.   

Abstract

BACKGROUND: Lung adenocarcinoma (LUAD) patients with different American Joint Committee on Cancer stages have different overall 5-year survival rates. The tumor microenvironment (TME) and intra-tumor heterogeneity (ITH) have been shown to play a crucial role in the occurrence and development of tumors. However, the TME and ITH in different lesions of LUAD have not been extensively explored.
METHODS: We present a 204,157-cell catalog of the TME transcriptome in 29 lung samples to systematically explore the TME and ITH in the different stages of LUAD. Traditional RNA sequencing data and complete clinical information were downloaded from publicly available databases.
RESULTS: Based on these high-quality cells, we constructed a single-cell network underlying cellular and molecular features of normal lung, early LUAD, and advanced LUAD cells. In contrast with early malignant cells, we noticed that advanced malignant cells had a remarkably more complex TME and higher ITH level. We also found that compared with other immune cells, more differences in CD8+/CTL T cells, regulatory T cells, and follicular B cells were evident between early and advanced LUAD. Additionally, cell-cell communication analyses, revealed great diversity between different lesions of LUAD at the single-cell level. Flow cytometry and qRT-PCR were used to validate our results.
CONCLUSION: Our results revealed the cellular diversity and molecular complexity of cell lineages in different stages of LUAD. We believe our research, which serves as a basic framework and valuable resource, can facilitate exploration of the pathogenesis of LUAD and identify novel therapeutic targets in the future.
© 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

Entities:  

Keywords:  advanced/early lung adenocarcinoma; heterogeneity; single-cell RNA-seq; the tumor microenvironment

Mesh:

Substances:

Year:  2021        PMID: 33783985      PMCID: PMC7943914          DOI: 10.1002/ctm2.350

Source DB:  PubMed          Journal:  Clin Transl Med        ISSN: 2001-1326


  58 in total

Review 1.  Hypoxia-inducible factors in physiology and medicine.

Authors:  Gregg L Semenza
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

2.  CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis.

Authors:  Subir Biswas; Suman Sengupta; Sougata Roy Chowdhury; Samir Jana; Gunjan Mandal; Palash Kumar Mandal; Nipun Saha; Vivek Malhotra; Arnab Gupta; Dmitry V Kuprash; Arindam Bhattacharyya
Journal:  Breast Cancer Res Treat       Date:  2013-12-13       Impact factor: 4.872

3.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

Review 4.  The biology and function of fibroblasts in cancer.

Authors:  Raghu Kalluri
Journal:  Nat Rev Cancer       Date:  2016-08-23       Impact factor: 60.716

5.  Single-cell RNA sequencing of lung adenocarcinoma reveals heterogeneity of immune response-related genes.

Authors:  Ke-Yue Ma; Alexandra A Schonnesen; Amy Brock; Carla Van Den Berg; S Gail Eckhardt; Zhihua Liu; Ning Jiang
Journal:  JCI Insight       Date:  2019-02-21

6.  ROS-responsive nanoparticles based on amphiphilic hyperbranched polyphosphoester for drug delivery: Light-triggered size-reducing and enhanced tumor penetration.

Authors:  Hua Jin; Ting Zhu; Xiange Huang; Mo Sun; Hegen Li; Xinyuan Zhu; Mingliang Liu; Yibin Xie; Wei Huang; Deyue Yan
Journal:  Biomaterials       Date:  2019-05-03       Impact factor: 12.479

7.  Differences of tumor microenvironment between stage I lepidic-positive and lepidic-negative lung adenocarcinomas.

Authors:  Shinya Katsumata; Keiju Aokage; Tomohiro Miyoshi; Kenta Tane; Hiroshi Nakamura; Masato Sugano; Motohiro Kojima; Satoshi Fujii; Takeshi Kuwata; Atsushi Ochiai; Ryuichi Hayashi; Masahiro Tsuboi; Genichiro Ishii
Journal:  J Thorac Cardiovasc Surg       Date:  2018-06-04       Impact factor: 5.209

8.  Regenerative lineages and immune-mediated pruning in lung cancer metastasis.

Authors:  Ashley M Laughney; Jing Hu; Nathaniel R Campbell; Samuel F Bakhoum; Manu Setty; Vincent-Philippe Lavallée; Yubin Xie; Ignas Masilionis; Ambrose J Carr; Sanjay Kottapalli; Viola Allaj; Marissa Mattar; Natasha Rekhtman; Joao B Xavier; Linas Mazutis; John T Poirier; Charles M Rudin; Dana Pe'er; Joan Massagué
Journal:  Nat Med       Date:  2020-02-10       Impact factor: 53.440

9.  Expression of secretoglobin3A2 (SCGB3A2) in primary pulmonary carcinomas.

Authors:  Motoko Tachihara-Yoshikawa; Takashi Ishida; Kana Watanabe; Aya Sugawara; Kenya Kanazawa; Ryuzo Kanno; Toshimitsu Suzuki; Tomoaki Niimi; Shioko Kimura; Mitsuru Munakata
Journal:  Fukushima J Med Sci       Date:  2008-12

10.  An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.

Authors:  Cyril Neftel; Julie Laffy; Mariella G Filbin; Toshiro Hara; Marni E Shore; Gilbert J Rahme; Alyssa R Richman; Dana Silverbush; McKenzie L Shaw; Christine M Hebert; John Dewitt; Simon Gritsch; Elizabeth M Perez; L Nicolas Gonzalez Castro; Xiaoyang Lan; Nicholas Druck; Christopher Rodman; Danielle Dionne; Alexander Kaplan; Mia S Bertalan; Julia Small; Kristine Pelton; Sarah Becker; Dennis Bonal; Quang-De Nguyen; Rachel L Servis; Jeremy M Fung; Ravindra Mylvaganam; Lisa Mayr; Johannes Gojo; Christine Haberler; Rene Geyeregger; Thomas Czech; Irene Slavc; Brian V Nahed; William T Curry; Bob S Carter; Hiroaki Wakimoto; Priscilla K Brastianos; Tracy T Batchelor; Anat Stemmer-Rachamimov; Maria Martinez-Lage; Matthew P Frosch; Ivan Stamenkovic; Nicolo Riggi; Esther Rheinbay; Michelle Monje; Orit Rozenblatt-Rosen; Daniel P Cahill; Anoop P Patel; Tony Hunter; Inder M Verma; Keith L Ligon; David N Louis; Aviv Regev; Bradley E Bernstein; Itay Tirosh; Mario L Suvà
Journal:  Cell       Date:  2019-07-18       Impact factor: 41.582

View more
  14 in total

1.  A Novel Prognostic Signature Revealed the Interaction of Immune Cells in Tumor Microenvironment Based on Single-Cell RNA Sequencing for Lung Adenocarcinoma.

Authors:  Xing Jin; Zhengyang Hu; Qihai Sui; Mengnan Zhao; Jiaqi Liang; Zhenyu Liao; Yuansheng Zheng; Hao Wang; Yu Shi
Journal:  J Immunol Res       Date:  2022-07-01       Impact factor: 4.493

2.  Forward single-cell sequencing into clinical application: Understanding of ageing and rejuvenation from clinical observation to single-cell solution.

Authors:  Furong Yan; Zhangping Li; Charles A Powell; Xiangdong Wang
Journal:  Clin Transl Med       Date:  2022-05

3.  Establishment and Application of a Prognostic Risk Score Model Based on Characteristics of Different Immunophenotypes for Lung Adenocarcinoma.

Authors:  Hong Gao; Yanhong Liu; Yue Hu; Meiling Ge; Jie Ding; Qing Ye
Journal:  Front Genet       Date:  2022-04-25       Impact factor: 4.772

4.  Can single cell RNA sequencing reshape the clinical biochemistry of hematology: New clusters of circulating blood cells.

Authors:  Hao Fang; Yiming Zeng; Lianzhong Zhang; Chengshui Chen; Charles A Powell; Xiangdong Wang
Journal:  Clin Transl Med       Date:  2021-12

5.  Clinical Prognostic Value of the PLOD Gene Family in Lung Adenocarcinoma.

Authors:  Yiming Meng; Jing Sun; Guirong Zhang; Tao Yu; Haozhe Piao
Journal:  Front Mol Biosci       Date:  2022-02-21

6.  Establishing a Macrophage Phenotypic Switch-Associated Signature-Based Risk Model for Predicting the Prognoses of Lung Adenocarcinoma.

Authors:  Jun Chen; Chao Zhou; Ying Liu
Journal:  Front Oncol       Date:  2022-02-23       Impact factor: 6.244

7.  Cisplatin resistance-related multi-omics differences and the establishment of machine learning models.

Authors:  Qihai Sui; Zhencong Chen; Zhengyang Hu; Yiwei Huang; Jiaqi Liang; Guoshu Bi; Yunyi Bian; Mengnan Zhao; Cheng Zhan; Zongwu Lin; Qun Wang; Lijie Tan
Journal:  J Transl Med       Date:  2022-04-11       Impact factor: 5.531

8.  Forward single-cell sequencing into clinical application: Understanding of cancer microenvironment at single-cell solution.

Authors:  Xuanqi Liu; Charles A Powell; Xiangdong Wang
Journal:  Clin Transl Med       Date:  2022-04

9.  miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways.

Authors:  Guoshu Bi; Jiaqi Liang; Mengnan Zhao; Huan Zhang; Xing Jin; Tao Lu; Yuansheng Zheng; Yunyi Bian; Zhencong Chen; Yiwei Huang; Valeria Besskaya; Cheng Zhan; Qun Wang; Lijie Tan
Journal:  Mol Ther Nucleic Acids       Date:  2022-03-28       Impact factor: 8.886

Review 10.  Deciphering the Immune-Tumor Interplay During Early-Stage Lung Cancer Development via Single-Cell Technology.

Authors:  Wei-Wei Chen; Wei Liu; Yingze Li; Jun Wang; Yijiu Ren; Guangsuo Wang; Chang Chen; Hanjie Li
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.